These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7645065)

  • 1. [Intracranial distribution of iohexol and iotrolan after cervical myelography].
    Fiirgaard B; Madsen HH; Svare U; Skjødt T; Zeeberg I
    Ugeskr Laeger; 1995 Jul; 157(27):3901-4. PubMed ID: 7645065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intrathecal distribution of iohexol after cervical myelography].
    Madsen HH; Olsen NK; Svare U; Zeeberg I
    Ugeskr Laeger; 1990 Aug; 152(35):2489-91. PubMed ID: 2402829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective comparison of iotrolan and iohexol in lumbar myelography.
    Wagner A; Jensen C; Saebye A; Rasmussen TB
    Acta Radiol; 1994 Mar; 35(2):182-5. PubMed ID: 8172748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iotrolan, a nonionic dimeric contrast medium in myelography.
    Bien S; Schumacher M; Berger W; Wenzel-Hora BI
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():158-60. PubMed ID: 2568785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference of contrast effects of myelography in normal dogs: comparison of iohexol (180 mgI/ml), iohexol (240 mgI/ml) and iotrolan (240 mgI/ml).
    Shimizu J; Yamada K; Kishimoto M; Iwasaki T; Miyake Y
    J Vet Med Sci; 2008 Jul; 70(7):659-63. PubMed ID: 18685236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse reactions and intracranial contrast medium after myelography].
    Fujii K; Hashimoto T; Isaza M; Hashimoto T; Hirabuki N; Miura T; Mitomo M; Kozuka T; Kawai R
    Rinsho Hoshasen; 1989 Mar; 34(3):323-7. PubMed ID: 2739082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracranial iohexol-distribution following cervical myelography, postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording.
    Olsen NK; Madsen HH; Eriksen FB; Svare U; Zeeberg I
    Acta Neurol Scand; 1990 Nov; 82(5):321-8. PubMed ID: 2281749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with iomeprol in myelography and myelo-CT: clinical pharmacology and double-blind comparisons with iopamidol, iohexol, and iotrolan.
    Katayama H; Heneine N; van Gessel R; Taroni P; Spinazzi A
    Invest Radiol; 2001 Jan; 36(1):22-32. PubMed ID: 11176258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the spread and period of retention of Iotrolan in the subarachnoid space on the side effects rate in myelography.
    Hoffmann B; Becker H; Wenzel-Hora BI
    Neuroradiology; 1987; 29(4):380-4. PubMed ID: 3627421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracranial iotrolan distribution following cervical myelography. Postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording.
    Fiirgaard B; Madsen HH; Svare U; Eriksen FB; Skjødt T; Zeeberg I
    Acta Radiol; 1995 Jan; 36(1):77-81. PubMed ID: 7833174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective comparison of iotrolan, iohexol and iopamidol for lumbar myelography.
    Lamb J; McAllister V; Nelson M; Bartlett R; Smith I; Deopugari CE
    Acta Radiol Suppl; 1986; 369():524-7. PubMed ID: 2980547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nonionic contrast agents iohexol and iotrolan for cisternal myelography in dogs.
    van Bree H; Van Rijssen B; Van Ham L
    Am J Vet Res; 1991 Jun; 52(6):926-33. PubMed ID: 1883098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal experimental myelography in the pig. A comparison between iohexol and iotrolan.
    Skalpe IO; Tang GJ
    Invest Radiol; 1995 Apr; 30(4):239-43. PubMed ID: 7635674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iotrolan. The first dimeric non-ionic contrast medium for the subarachnoid space.
    Wenzel-Hora BI
    Acta Radiol Suppl; 1986; 369():545-8. PubMed ID: 2980554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to iotrolan after subarachnoid injection in animals.
    Press WR; Mützel W; Schöbel C
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():126-33. PubMed ID: 2568780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iohexol: a new nonionic contrast medium for myelography and cisternography with markedly reduced neurotoxicity.
    Gonsette RE; Liesenborghs L
    Invest Radiol; 1985; 20(1 Suppl):S32-6. PubMed ID: 3871751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with iotrolan in myelographic and computed tomography applications in the United States.
    Goldstein HA; Pfennig D
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():167-70. PubMed ID: 2568788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iotrolan versus iopamidol: a controlled, multicenter, double-blind study of lumbar and direct cervical myelography.
    Ringel K; Klotz E; Wenzel-Hora BI
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():153-7. PubMed ID: 2568784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and excretion of iohexol after lumbar myelography in man.
    Shaw DD; Kido DK; Stroshane RM; Palace GP; Sahler L
    Invest Radiol; 1985 Sep; 20(6):632-7. PubMed ID: 2933362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iohexol: summary of North American and European clinical trials in adult lumbar, thoracic, and cervical myelography with a new nonionic contrast medium.
    Shaw DD; Bach-Gansmo T; Dahlstrom K
    Invest Radiol; 1985; 20(1 Suppl):S44-50. PubMed ID: 3882616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.